(Q33962212)

30 July 2017

1 reference

title

Pharmacogenetics and psychopharmacotherapy (English)

1 reference

30 July 2017

N Poolsup

1

1 reference

30 July 2017

A Li Wan Po

series ordinal

2

1 reference

30 July 2017

T L Knight

series ordinal

3

1 reference

30 July 2017

publication date

1 June 2000

1 reference

Journal of Clinical Pharmacy and Therapeutics

30 July 2017

published in

1 reference

30 July 2017

volume

25

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

197-220

1 reference

Individual variation in first-pass metabolism

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacokinetics and renal function in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Gender effects in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Racial, ethnic and gender differences in response to medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Plasma protein binding and pharmacological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Influence of pharmacogenetics on drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Defective oxidation of drugs: pharmacokinetic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacogenetics: its biologic roots and the medical challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Interethnic variation of drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Ethnic differences in drug disposition and responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacogenetics in clinical pharmacology and toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacogenetic phenotyping and genotyping. Present status and future potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Clinical importance of hepatic cytochrome P450 in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Recent advances: the cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacogenetics: the slow, the rapid, and the ultrarapid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Genetic Aspects of Drug Disposition and Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Debrisoquine oxidation in an Australian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Sparteine metabolism in Canadian Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Oxidation phenotyping in Chinese and Malay populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Polymorphism of dextromethorphan oxidation in a French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Evidence for polymorphic oxidation of sparteine in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Sparteine oxidation polymorphism in Greenlanders living in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

A study of the debrisoquine hydroxylation polymorphism in a Nigerian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Debrisoquine and mephenytoin oxidation in Sinhalese: a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Evidence for the polymorphic oxidation of debrisoquine in the Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Differences in drug metabolism polymorphism between Orientals and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Clinical implications of antidepressant pharmacokinetics and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Desipramine pharmacokinetics in Chinese and Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacokinetics of desipramine in Caucasian and Asian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Tricyclic plasma levels. Effect of age, race, sex, and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Haloperidol concentrations elevated in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Haloperidol kinetics after oral and intravenous doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

A pharmacokinetic study of trifluoperazine in two ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Diazepam effects and kinetics in Caucasians and Orientals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with occidentals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Neuroleptic dosage for Asians: a failure to replicate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Diagnosis and pharmacotherapy issues in the care of Hispanics in the public sector

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Ethnicity and antipsychotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Multiple dopamine D4 receptor variants in the human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Extrapyramidal reactions in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Transcultural psychopharmacology: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

The impact of pharmacogenetics on the future of healthcare

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2000.00281.X

10.1046/J.1365-2710.2000.00281.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference